The brain fungus flagged by federal researchers this month has a better-known cousin causing quieter trouble in America’s hospitals: Candida auris, a drug-resistant yeast whose clinical cases more than doubled in the United States between 2022 and 2024.
The figures come from a CDC study published in July, cited in the agency’s latest reporting on fungal threats. California, Texas and Nevada reported the most cases in 2024. Unlike most yeasts, Candida auris spreads readily within healthcare facilities — colonising skin, lingering on surfaces and equipment, and resisting several of the antifungal drugs clinicians would normally reach for first.
The patients at risk are typically the most vulnerable people in the building: those in intensive care, on ventilators, with central lines or long stays in skilled-nursing facilities. Invasive infections carry high mortality, and because the organism can be misidentified by standard laboratory methods, it has repeatedly gained ground in facilities before anyone knew it had arrived.
Health officials treat Candida auris as a model of the wider problem now appearing across mycology: fungal infections that were once medical curiosities are becoming routine infection-control battles. The same CDC report that documented a fourfold rise in a rare brain fungus pointed to the yeast’s trajectory as evidence that the trend crosses species and settings.
The tools of response are unglamorous — screening admissions from high-risk units, single rooms, meticulous disinfection with the agents that actually work against it, and laboratories equipped to name it correctly. Fungal disease rarely wins headlines. Inside hospitals, it is winning something more important: attention, budgets, and a permanent place on the infection-control agenda.
Related reading: Gut Bacteria May Reveal How Fast the Brain Is Aging, UCLA Study Suggests · FDA Decision Day Arrives for a Colon Cancer Immunotherapy Combination · CDC Flags a Sharp Rise in a Rare Brain Fungus With a Grim Fatality Rate
